Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Tamara Minko"'
Autor:
Aleksandra Romaniuk-Drapala, Paulina Skupin-Mrugalska, Olga Garbuzenko, Arash Hatefi, Tamara Minko
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Olaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grad
Externí odkaz:
https://doaj.org/article/2350485a9cd741f996cbc87a97309a02
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 19, p 10357 (2024)
Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine, and beta-site amyloid precursor protein-cleaving enzyme (BACE-1) siRNA, and their combinat
Externí odkaz:
https://doaj.org/article/a2dbfc7eb5a24c388552bd7233522df3
Autor:
Xin Gu, Joydeb Majumder, Olena Taratula, Andriy Kuzmov, Olga Garbuzenko, Natalia Pogrebnyak, Tamara Minko
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5545 (2024)
A novel nanotechnology-based drug delivery system (DDS) targeted at pancreatic cancer cells was developed, characterized, and tested. The system consisted of liposomes as carriers, an anticancer drug (paclitaxel) as a chemotherapeutic agent, and a mo
Externí odkaz:
https://doaj.org/article/2e8f5f3eb47f435d92cfe79f35388cde
Autor:
Vitaly P. Pozharov, Tamara Minko
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 194 (2023)
Over the past decades, many drugs based on the use of nanotechnology and nucleic acids have been developed. However, until recently, most of them remained at the stage of pre-clinical development and testing and did not find their way to the clinic.
Externí odkaz:
https://doaj.org/article/705e334b3c744b47893df2af48c86a41
Autor:
David Lee, Tamara Minko
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2049 (2021)
Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits the penetration of therapeutic molecules to the brain after oral or pa
Externí odkaz:
https://doaj.org/article/0f895063e9dc4fb4a2bf2447838c790e
Autor:
Joydeb Majumder, Tamara Minko
Publikováno v:
Pharmaceutics, Vol 13, Iss 7, p 1063 (2021)
Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment especially in advanced stages of cancer. Overcoming or suppressing RPIAM can dram
Externí odkaz:
https://doaj.org/article/b41f3542c03c4ad486da88f6aa453f58
Autor:
Paulina Skupin-Mrugalska, Tamara Minko
Publikováno v:
Pharmaceutics, Vol 12, Iss 10, p 939 (2020)
Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. OSI has been app
Externí odkaz:
https://doaj.org/article/31c634ce39ad45c0ab1b33267a700674
Publikováno v:
Cancer Biology & Medicine, Vol 11, Iss 1, Pp 44-55 (2014)
Objective Various nanoparticles have been designed and tested in order to select optimal carriers for the inhalation delivery of anticancer drugs to the lungs. Methods The following nanocarriers were studied:micelles, liposomes, mesoporous silica nan
Externí odkaz:
https://doaj.org/article/c00ba8b48a9c4b74b9f78041d9b6506a
Publikováno v:
Journal of Controlled Release. 359:1-11
Autor:
Simav Gildiz, Tamara Minko
Publikováno v:
Pharmaceutical Research. 40:123-144
Anticancer vaccines represent a promising approach for effective treatment of cancer and along with recent advantages of nucleic acid-based vaccines for other diseases form a prospective and potentially efficacious direction of the research, developm